ArticleToxics2025
The Development and Toxicological Evaluation of Novel Polyurethane Materials.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polyurethane (PU) is widely employed in the biomedical field. As application scenarios become increasingly complex, it is essential to modify PU to meet diverse requirements. Additionally, the degradation of PU is closely linked to the sustainability of its function, with degradation products having a direct impact on adjacent tissues. In this study, a novel PU containing double bonds in its main chain was developed. We investigated the influence of various ratios of soft segment composition on the degradation performance of PU, maintaining a fixed ratio of soft to hard segments and utilizing specific synthesis methods. The structure and molecular weight of the PU were analyzed using FTIR, NMR, and GPC techniques. The results of physical and chemical performance tests indicated that an increase in polycaprolactone diol (PCL diol) content within the soft segment enhanced the mechanical properties, hydrophobicity, and degradation performance of the PU. A further assessment of the degradation toxicity of PU was carried out using zebrafish as a model organism. The findings indicated that the degradation solution of PU exhibited slight toxicity to zebrafish embryonic development over prolonged degradation periods. However, it also significantly enhanced the hatching of zebrafish embryos. In summary, the novel PU developed in this study demonstrates favorable biocompatibility, and the approach of introducing reaction sites or modifying the composition of its soft segments within the molecular structure offers a promising and effective strategy to address specific application requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.